Chronic Lymphocytic Leukemia

We recommend hematologie

OHD 2024: What’s New in Data and Experiences from Real Practice with Venetoclax Regimens?

19. 6. 2024 Source: Chronic Lymphocytic Leukemia

How to utilize venetoclax regimens most effectively for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in real practice was the topic of a satellite symposium organized by AbbVie during this year’s XXXVIth Olomouc Hematology Days. Three hemato-oncologists shared their experiences with venetoclax treatment, moderated by Prof. MUDr. Tomáš Papajík, CSc., from the Department of Hemato-Oncology, Faculty of Medicine, Palacky University and University Hospital Olomouc.

CLL

Benefits of Time-Limited CLL Therapy

The advent of new targeted molecules has significantly influenced the possibilities of therapy for…
5. 3. 2024 Source: Chronic Lymphocytic Leukemia
červená kniha

Selecting from the Red Book CHS: What's New in This Year's Recommendations for the Diagnosis and Treatment of CLL?

Chronic lymphocytic leukemia (CLL) is the most common lymphoid malignancy in adults in Europe and…
7. 12. 2023 Source: Chronic Lymphocytic Leukemia

Articles on this topic
CLL

Educational Brochure for Patients with CLL

Thanks to the expansion of modern therapies for chronic lymphocytic leukemia, many patients now...
28. 11. 2023 Source: Chronic Lymphocytic Leukemia
mobilní aplikaci

Venetostart – The First Comprehensive Mobile Application with Practical Information for Venetoclax Treatment

Abbvie has developed the comprehensive mobile application Venetostart with practical…
27. 2. 2023 Source: Chronic Lymphocytic Leukemia
Guidelines_kompas

Current NCCN Recommendations for Classification and Risk Symptoms in SLL/CLL

The new recommendations from the National Comprehensive Cancer Network (NCCN) regarding…
12. 1. 2023 Source: Chronic Lymphocytic Leukemia
CLL v evropě

Incidence of Secondary Malignancies in CLL Patients on FCR Regimen in Central Europe

Chronic lymphocytic leukemia (CLL) represents the most common type of leukemia in Western…
7. 12. 2022 Source: Chronic Lymphocytic Leukemia
Guidelines

Current NCCN Recommendations for CLL/SLL Diagnosis – Version 1.2023

In August 2022, the latest guidelines from the National Comprehensive Cancer Network (NCCN)…
23. 11. 2022 Source: Chronic Lymphocytic Leukemia
léčebné možnosti

Current Treatment Options for Refractory/Relapsed CLL

How have treatment protocols for chronic lymphocytic leukemia changed in recent years? A…
8. 9. 2022 Source: Chronic Lymphocytic Leukemia
venclyxto kazuistika

Sequential administration of immunochemotherapy and venetoclax after failure of BCR inhibitor treatment – interactive video case study

The treatment of chronic lymphocytic leukemia (CLL) is evolving. What was impossible years ago…
5. 8. 2022 Source: Chronic Lymphocytic Leukemia
otazníky

What can we base the decision on for the choice of initial treatment modality for CLL?

We now have a range of highly effective treatment options for patients with chronic…
18. 5. 2022 Source: Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL)

Venetoclax Treatment Strategies in Patients with CLL

One of the new targeted preparations in the treatment of chronic lymphocytic leukemia (CLL) is…
20. 4. 2022 Source: Chronic Lymphocytic Leukemia
American Society of Hematology

Brief from ASH 2021: News and Advances in CLL Treatment

The summary from the first day of the 63rd American Society of Hematology (ASH) Congress in…
12. 4. 2022 Source: Chronic Lymphocytic Leukemia

1 2 3
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account